
Soligenix Reports Positive Extended Phase 2a Results for SGX302 Gel in Psoriasis Treatment
Soligenix Inc. announced extended Phase 2a trial results showing its SGX302 topical gel formulation was well tolerated and demonstrated clinical improvements for mild-to-moderate psoriasis, supporting its development as a potential non-carcinogenic therapeutic option.
Read full story
























